PACS Group Earnings Call Highlights Profitable, Disciplined Growth

PACS Group Inc ((PACS)) has held its Q4 earnings call. Read on for the main highlights of the call.

PACS Group Inc’s latest earnings call struck an upbeat tone as management highlighted record revenues, stronger margins and improving clinical metrics, while acknowledging short-term pressure from higher costs and softer occupancies in newer facilities. Executives framed 2026 as a year of disciplined, steady growth built on a conservative balance sheet and a maturing, increasingly efficient portfolio.

Record Revenue and Profitability

PACS posted full-year 2025 revenue of $5.29 billion, up about 29% from the prior year, with fourth quarter sales climbing roughly 12% to $1.36 billion. Net income reached $191.5 million, or $1.22 per diluted share, and the company reported record adjusted EBITDAR of $883.9 million and adjusted EBITDA of $505 million, underscoring solid margin performance.

Strong Guidance for 2026

For 2026, management projected revenue between $5.65 billion and $5.75 billion, implying around 8% growth at the midpoint compared with 2025. Adjusted EBITDA is expected in a $555 million to $575 million range, targeting roughly 12% growth and signaling further margin expansion as the portfolio mix improves and operations scale.

High and Improving Clinical Quality

Clinical outcomes remained a key differentiator, with 207 facilities, or about 73.4% of the portfolio, rated four or five stars on CMS quality measures. In mature facilities, the average CMS quality measure star rating increased to 4.4 in 2025 from 4.3 in 2024, comfortably above an industry average near 3.5 and supporting the company’s premium positioning.

Strong Occupancy in Mature Portfolio

Overall portfolio occupancy averaged 89.1% for 2025, but performance was notably stronger in mature facilities, which delivered 94.9% occupancy. That mature cohort figure rose 0.5 percentage points from 94.4% a year earlier, highlighting durable demand and efficient operations in stabilized assets despite broader sector volatility.

Scale and Platform Footprint

By the end of 2025, PACS operated 321 facilities across 17 states, totaling 35,379 operating beds split between 32,854 skilled nursing beds and 2,525 assisted living beds. The platform cared for more than 31,700 patients daily and employed over 47,000 people, giving the company meaningful scale advantages in purchasing, staffing and clinical programs.

Disciplined Balance Sheet and Low Leverage

Management emphasized financial discipline, reporting year-end net leverage of approximately 0.3 times even after significant acquisition and capital spending. The company deployed more than $145 million in the quarter on real estate and other investments while preserving a conservative leverage profile that offers flexibility for future opportunities.

Successful Integration and Operational Wins

PACS completed eight strategic acquisitions in 2025, all in existing markets, while continuing to integrate deals closed in 2024. Operational highlights included seven zero-deficiency surveys during the year and an Oceanside, California de novo facility that turned profitable in its first year, aided by more than 250 admissions in 2025.

Growing Real Estate Ownership and Long Lease Profiles

The company now wholly or partially owns real estate interests in 102 facilities, expanding its ownership base and potential value creation from property. Average remaining lease terms stand at about 13 years for operating leases and around 22 years for finance leases, providing long-term stability and optionality to further reduce lease-adjusted leverage.

Occupancy Pressure in Ramping and New Cohorts

While mature facilities performed well, occupancy in ramping facilities fell to 86.3% in 2025 from more than 93% in the prior year, as cohort movement and portfolio mix shifts weighed on averages. Newly acquired or developed facilities averaged 81.1% occupancy versus 82.8% in 2024, reflecting normal onboarding and stabilization challenges.

Rising Operating and Administrative Costs

Costs moved higher as the platform grew, with cost of services rising 25% year over year and general and administrative expenses up 21%. Management tied the increases to investments in clinical, compliance and corporate infrastructure, noting that these outlays pressure near term margins but are intended to support sustainable growth and performance.

Acquisitions Enter at Depressed Occupancies

Executives highlighted that many acquisition targets come in with materially depressed occupancies, often in the 60% to 70% range. These facilities are typically modeled with nominal revenue contribution and essentially zero margin at the outset, creating short term dilution but offering upside as PACS improves operations and fills beds over time.

M&A Pricing and Selectivity

Management described an acquisition market where pricing has risen in recent years due to inflation and real estate dynamics but now appears to be plateauing at still elevated levels. PACS closes only a small fraction of its sizable deal pipeline, underscoring a selective approach as it navigates competitive conditions and remains disciplined on returns.

De Novo Development Still Limited

Although the Oceanside de novo was a clear success, leadership cautioned that new builds are not expected to be a major growth engine due to high capital requirements and regulatory complexity. De novo projects will be pursued selectively where risk adjusted returns are compelling, with acquisitions and optimization of existing assets remaining the primary strategy.

Cohort Transitions Blur Comparisons

Management noted that year over year comparisons can be distorted as facilities move from new to ramping to mature cohorts, changing the composition of each group. This dynamic can make occupancy trends in non mature segments appear weaker even when underlying performance is improving, and investors were urged to consider cohort evolution when interpreting metrics.

Guidance and Outlook

Looking ahead to 2026, the company’s guidance assumes steady organic growth, gradual margin expansion driven by better occupancy and skilled mix, and stable reimbursement trends. PACS also baked in a modest acquisition cadence of roughly 20 facilities per year, typically acquired at low initial occupancies, supported by its scaled platform and low net leverage position.

PACS Group’s earnings call painted a picture of a scaled operator delivering record results, steadily improving clinical quality and maintaining a fortress-like balance sheet. While rising costs and lower occupancies in newer assets temper near-term metrics, management’s cautious approach to growth and constructive 2026 outlook may reassure investors focused on long term value creation.